Bekemv vs Ultomiris: Side-by-Side Comparison
Quick answer: Bekemv and Ultomiris are both complement c5 inhibitor (monoclonal antibody) used for similar indications. They share a mechanism of action but differ in dosing, half-life, side-effect profile, and clinical preferences. Switching between them is a clinical decision.
Side-by-side comparison
| Feature | Bekemv | Ultomiris |
|---|---|---|
| Drug class | Complement C5 inhibitor (monoclonal antibody) | Complement C5 inhibitor (monoclonal antibody) |
| ATC code | L04AJ01 | L04AJ02 |
| Primary indications | Paroxysmal nocturnal hemoglobinuria, Atypical hemolytic uremic syndrome | Paroxysmal nocturnal hemoglobinuria, Atypical hemolytic uremic syndrome |
| Mechanism | Humanized monoclonal antibody (eculizumab biosimilar) that binds complement protein C5 to prevent terminal complement activation | Long-acting humanized monoclonal antibody binding complement C5 to prevent terminal complement activation |
| Common dose | 600 mg IV weekly x4, then 900 mg every 2 weeks (PNH maintenance) | Weight-based IV every 8 weeks (maintenance) |
| Detail page | Bekemv details → | Ultomiris details → |
How to choose between Bekemv and Ultomiris
Both medicines belong to the same therapeutic class and address overlapping indications. Selection between them depends on:
- Patient-specific factors: age, kidney and liver function, other medications, allergies, comorbidities
- Specific clinical indication: some class members are preferred for particular conditions or guideline recommendations
- Dosing preference: once-daily vs twice-daily, oral vs injectable, food requirements
- Tolerability: individual side-effect profiles vary even within a class
- Drug interactions: patient's other medications may interact differently with each option
- Cost and availability: generic availability, insurance coverage, regional access
Should you switch?
Switching between class members is a clinical decision, not a self-help one. Reasons your prescriber may consider switching include:
- Inadequate response to current medication
- Side effects affecting quality of life
- New drug interactions due to a recently added medication
- Cost or availability changes
- Updated guidelines favoring a different option
Never switch medications, change dose, or stop without consulting your prescriber.
Related
All Complement C5 inhibitor (monoclonal antibody) on iMedic · Bekemv full details · Ultomiris full details
Frequently asked questions
Is Bekemv better than Ultomiris?
Neither is universally 'better.' They are both complement c5 inhibitor (monoclonal antibody) with similar mechanisms of action. The right choice depends on the specific clinical situation, patient factors, dosing preferences, drug interactions, and tolerability. Discuss with your prescriber.
Can I switch from Bekemv to Ultomiris?
Switching is possible but should be done under clinical supervision. Different class members may not be interchangeable on a 1:1 dose basis, and tapering or transition strategies vary. Never switch on your own.
Do Bekemv and Ultomiris have the same side effects?
They share class-wide side-effect tendencies but differ in individual profiles. Some patients tolerate one better than the other. Specific frequency and severity of side effects can be found on each medicine's individual page.
Are Bekemv and Ultomiris available as generics?
Generic availability depends on patent status in your country. Most well-established class members are available generically and are clinically equivalent to brand-name versions.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.